Emergent BioSolutions Inc.

EBS

US29089Q1058

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-06-21 pm EDT			5-day change	1st Jan Change
6.52 ^USD	+0.77%		+5.67%	+171.67%

Jun. 20	Benchmark Adjusts Emergent Biosolutions Price Target to $8 From $5, Maintains Buy Rating	MT
May. 02	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Emergent BioSolutions Inc. Provides Earnings Guidance for the Year 2021

January 10, 2021 at 02:00 pm EST

Emergent BioSolutions Inc. provided earnings guidance for the year 2021. For the year, the company expects total revenues in the range of $1,950 million - $2,050 million, net income in the range of $420.0 million to $470.0 million.

Latest news about Emergent BioSolutions Inc.

Benchmark Adjusts Emergent Biosolutions Price Target to $8 From $5, Maintains Buy Rating	Jun. 20	MT
Sector Update: Health Care Stocks Softer Late Afternoon	May. 02	MT
Sector Update: Health Care	May. 02	MT
Top Midday Gainers	May. 02	MT
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected	May. 02	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Earnings Deluge Continues	May. 02	MT
Fed Decision Eases Investor Anxiety as US Futures Trend Higher in Thursday's Premarket	May. 02	MT
Top Premarket Gainers	May. 02	MT
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Posts Q1 EPS $0.59	May. 01	MT
Transcript : Emergent BioSolutions Inc., Q1 2024 Earnings Call, May 01, 2024	May. 01
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q1 Revenue $300.4M, vs. Street Est of $224.5M	May. 01	MT
Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024	May. 01	CI
Emergent BioSolutions Inc. Provides Revenue Guidance for the Second Quarter of 2024	May. 01	CI
Emergent BioSolutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Emergent BioSolutions to lay off about 300 employees	May. 01	RE
Emergent BioSolutions to cut 300 jobs	May. 01	RE
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position	May. 01	CI
Emergent BioSolutions Inc. Enters into A Consent, Waiver and Seventh Amendment to the Amended and Restated Credit Agreement	Apr. 30	CI
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	Apr. 24	MT
Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	Mar. 25	MT
Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	Mar. 25	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 12	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 12	MT
Emergent BioSolutions Tumbles After S&P Global Credit Downgrade	Mar. 12	MT
Emergent BioSolutions Shares Drop on S&P Downgrade	Mar. 12	DJ

Chart Emergent BioSolutions Inc.

Duration

Period

More charts

Company Profile

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Emergent BioSolutions Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.52 USD

Average target price

8 USD

Spread / Average Target

+22.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EMERGENT BIOSOLUTIONS INC.	+171.67%	342M
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals